ÌÇÐÄvlog´«Ã½

France Drug Delivery Devices Market Analysis

The French drug delivery devices market is anticipated to expand at a CAGR of 5.2% over the forecast period.

With the emergence of the COVID-19 pandemic, most pharmaceutical companies and governments have been/are working to provide adequate medical therapy to COVID-19 patients, and drug delivery devices are likely to play an essential role in this context. For example, large-scale vaccination programs are being implemented worldwide to immunize people against the SARS-COV-2 virus. However, many companies are still working on more efficient ways of delivering COVID-19 therapeutics to patients and are investing heavily in it, which is expected to impact the drug delivery market significantly. For instance, in January 2022, the BioMAP research team from the Infectiology and Public Health (ISP) joint research unit run by INRAE and the Université de Tours developed a protein vaccine candidate for nasal administration to project against COVID-19 blocking all transmission of the virus. The Ministry of Higher Education, Research, and innovation supports the project and is accompanied by the National Agency for AIDS Research (ANRS). As a result, COVID-19 was predicted to impact the drug delivery market's growth substantially. Additionally, the market is anticipated to resume its rise during the projection period as more research and development is undertaken on COVID-19 vaccines and all restrictions are removed.

The rising prevalence of chronic diseases, technological advancements, and growth in the biologics market are some key factors driving the development of the France drug delivery devices market. Many disorders, including cardiovascular disease and diabetes, can benefit from targeted drug administration. The most important application of targeted medication delivery is the treatment of malignant tumors. As a result, the increasing prevalence of these disorders is likely to drive market expansion throughout the forecast period. For instance, the high burden of cancer can be explained by the latest statistics provided by the International Agency for Research on Cancer published GLOBOCAN 2020 report, which stated that in 2020, there were an estimated 467,965 new cancer cases diagnosed, where the male population accounted for 260,169 cases followed by female population with 207,796 cases. This shows a high burden of cancer among the target population. As a result, the population's increasing reliance on various drug types, including chemotherapy and intravenous therapy, is projected to fuel the market's expansion.

Thus, all the mentioned factors are expected to boost market growth over the forecast period. However, the risk of needlestick injury may restrain market growth over the forecast period.

France Drug Delivery Devices Market Trends

This section covers the major market trends shaping the France Drug Delivery Devices Market according to our research experts:

Diabetes Segment is Estimated to Witness Healthy Growth over the Forecast Period

France Drug Delivery Devices Industry Segmentation

As per the scope of the report, drug delivery devices or systems are the tools that are used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. The market is segmented by route of administration (injectable, topical, and other routes of administration), application (cancer, cardiovascular, diabetes, infectious diseases, and other applications), and end user (hospitals, ambulatory surgical centers, and other end users). The report offers the value (in USD million) for the above segments.